MediWound Ltd. (NASDAQ:MDWD) - Stock analysts at SunTrust Banks dropped their FY2017 earnings per share (EPS) estimates for MediWound in a research report issued to clients and investors on Monday. SunTrust Banks analyst B. Nudell now forecasts that the biopharmaceutical company will earn ($0.80) per share for the year, down from their prior forecast of ($0.78). SunTrust Banks currently has a “Buy” rating on the stock. SunTrust Banks also issued estimates for MediWound’s Q4 2017 earnings at ($0.21) EPS.
MediWound (NASDAQ:MDWD) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.01. The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. MediWound’s revenue for the quarter was up 93.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.34) EPS.
Several other equities research analysts have also recently issued reports on the company. Zacks Investment Research cut MediWound from a “hold” rating to a “sell” rating in a research note on Tuesday. Aegis reissued a “buy” rating and set a $11.00 target price on shares of MediWound in a research note on Thursday, May 25th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on MediWound and gave the stock a “buy” rating in a research note on Monday, May 8th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $10.19.
MediWound (NASDAQ MDWD) opened at 6.70 on Thursday. MediWound has a one year low of $4.25 and a one year high of $8.58. The stock’s market cap is $146.93 million. The stock has a 50 day moving average price of $6.94 and a 200-day moving average price of $6.46.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDWD. Wellington Management Group LLP raised its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Renaissance Technologies LLC raised its position in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Finally, Wells Fargo & Company MN raised its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Institutional investors and hedge funds own 27.32% of the company’s stock.
About MediWound
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
